Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Biocept stock

Learn how to easily invest in Biocept stock.

Biocept Inc is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 104 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Biocept

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BIOC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Biocept stock price (NASDAQ: BIOC)

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

Information last updated 2022-01-21.
Latest market close$2.86
52-week range$2.98 - $8.38
50-day moving average $3.73
200-day moving average $4.03
Wall St. target price$13.00
PE ratio 13.79
Dividend yield N/A (0%)
Earnings per share (TTM) $0.22

Buy Biocept shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biocept price performance over time

Historical closes compared with the close of $2.86 from 2022-01-26

1 week (2022-01-21) -5.30%
1 month (2021-12-28) -21.86%
3 months (2021-10-28) -25.13%
6 months (2021-07-28) -31.58%
1 year (2021-01-28) -51.53%
2 years (2020-01-28) 778.11%
3 years (2019-01-28) 35.55%
5 years (2017-01-27) 83.33%

Is Biocept stock undervalued or overvalued?

Valuing Biocept stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biocept's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biocept's P/E ratio

Biocept's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biocept shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Biocept's EBITDA

Biocept's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.7 million.

The EBITDA is a measure of a Biocept's overall financial performance and is widely used to measure a its profitability.

Biocept financials

Revenue TTM $65.8 million
Operating margin TTM 5.15%
Gross profit TTM $6.1 million
Return on assets TTM 4.47%
Return on equity TTM 10.1%
Profit margin 4.71%
Book value $2.40
Market capitalisation $50.9 million

TTM: trailing 12 months

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as $2.98 up to $8.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.4465. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus.

Frequently asked questions

What percentage of Biocept is owned by insiders or institutions?
Currently 0.037% of Biocept shares are held by insiders and 12.076% by institutions.
How many people work for Biocept?
Latest data suggests 104 work at Biocept.
When does the fiscal year end for Biocept?
Biocept's fiscal year ends in December.
Where is Biocept based?
Biocept's address is: 9955 Mesa Rim Road, San Diego, CA, United States, 92121
What is Biocept's ISIN number?
Biocept's international securities identification number is: US09072V5012
What is Biocept's CUSIP number?
Biocept's Committee on Uniform Securities Identification Procedures number is: 09072V105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site